UNIVERSITY OF ALABAMA AT BIRMINGHAM

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1969-01-01

Employees: 2K

Market Cap: -

Website: http://www.uab.edu

Clinical Trials

Antiviral Effects of TXA as a Preventative Treatment Following COVID-19 Exposure

Phase 3

Withdrawn

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: Tranexamic acid

First Posted Date: 2020-09-16

Last Posted Date: 2021-04-23

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT04550338

Gait Training Combined With Behavioral Strategies for People With Stroke

Not Applicable

Completed

Conditions: Gait, Hemiplegic
Behavior and Behavior Mechanisms
Stroke

Interventions: Device: Treadmill training (TT)
Combination Product: Treadmill training + transfer package (TT+TP)

First Posted Date: 2020-09-11

Last Posted Date: 2024-05-22

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 19

Registration Number: NCT04546217

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

A Phase II Trial of Poly-ICLC for Low-Grade Gliomas

Phase 2

Terminated

Conditions: NF1
Low-grade Glioma

Interventions: Drug: Poly ICLC

First Posted Date: 2020-09-10

Last Posted Date: 2025-03-21

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 3

Registration Number: NCT04544007

Locations: 🇺🇸
The University of Alabama at Birmingham (Site 700), Birmingham, Alabama, United States
🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
Children's National Medical Center (Site 775), Washington, District of Columbia, United States

and more 9 locations

Glycemic Control After Antenatal Corticosteroids in Women with Pregestational and Gestational Diabetes

Phase 2

Recruiting

Conditions: Diabetes Mellitus, Type 2
Preterm Birth
Pregnancy, High Risk
Diabetes, Gestational

Interventions: Drug: Up-Titration of Home Insulin
Drug: Continuous Insulin Infusion
Drug: Sliding Scale Insulin
Device: Dexcom G6 Professional Continuous Glucose Monitor

First Posted Date: 2020-09-09

Last Posted Date: 2024-10-08

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 120

Registration Number: NCT04542148

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
University of South Carolina Greenville / Prisma Health-Upstate, Greenville, South Carolina, United States

and more 1 locations

Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer

Phase 1

Withdrawn

Conditions: Ovarian Cancer

Interventions: Drug: [11C]PiB and 18F-labeled DPA-714 PET scan

First Posted Date: 2020-09-09

Last Posted Date: 2024-04-25

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT04542603

COVID-19 Study of Safety and Tolerability of Alvelestat

Phase 1

Completed

Conditions: Covid19

Interventions: Drug: Placebo
Drug: Alvelestat

First Posted Date: 2020-09-07

Last Posted Date: 2023-01-19

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 15

Registration Number: NCT04539795

Locations: 🇺🇸
UAB Lung Health Center, Birmingham, Alabama, United States

Postpartum Glycemia in Women At Risk for Persistent Hyperglycemia

Not Applicable

Completed

Conditions: Gestational Diabetes

Interventions: Diagnostic Test: 2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor

First Posted Date: 2020-08-20

Last Posted Date: 2024-12-18

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 40

Registration Number: NCT04521712

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Exercise and Posture in Individuals with Osteoporosis

Not Applicable

Withdrawn

Conditions: Osteoporosis

Interventions: Behavioral: Instructional handouts
Behavioral: Physical therapist instruction and monitoring via teleconferencing
Behavioral: Web-based instructional videos
Behavioral: Posture training
Behavioral: Marching in place

First Posted Date: 2020-08-12

Last Posted Date: 2024-12-24

Lead Sponsor: University of Alabama at Birmingham

Registration Number: NCT04509427

Phase II Panitumumab-IRDye800 in Head & Neck Cancer

Phase 2

Recruiting

Conditions: Head and Neck Cancer

Interventions: Drug: Panitumumab-IRDye800

First Posted Date: 2020-08-12

Last Posted Date: 2025-04-16

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 25

Registration Number: NCT04511078

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Examining the Neural Effects of a Behavioral Intervention for Physical Activity in Multiple Sclerosis

Not Applicable

Completed

Conditions: Multiple Sclerosis

Interventions: Behavioral: Behavioral Intervention for Physical Activity in MS (BIPAMS)
Behavioral: Wellness for MS (WellMS)

First Posted Date: 2020-08-03

Last Posted Date: 2022-02-04

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 24

Registration Number: NCT04496804

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy